5
Orphan Designations
0 approved, 5 designated
0
FDA Approvals
0
Active Trials
2
Rare Diseases
across 3 areas
0
News (30d)
Quiet
Suzhou Immunofoco Biotechnology Co., Ltd is a company with 5 orphan drug designations across 2 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| gastric cancer | Autologous EpCAM specific CAR-T cell injectionAutologous synthetic NKG2D receptor armored CLDN18.2 specific CAR-T cell injectionAutologous Claudin 18.2 specific chimeric antigen receptor (CAR)-T cell therapy | Des.TrialAppr. |
| malignant pancreatic neoplasm | Autologous Claudin 18.2 specific CAR-T cellAutologous synthetic NKG2D receptor armored CLDN18.2 specific CAR-T cell injection | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
27
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
27
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio